-
1 Comment
Collegium Pharmaceutical, Inc is currently in a long term uptrend where the price is trading 4.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.7.
Collegium Pharmaceutical, Inc's total revenue rose by 2.8% to $76M since the same quarter in the previous year.
Its net income has increased by 416.1% to $7M since the same quarter in the previous year.
Finally, its free cash flow grew by 42.9% to $21M since the same quarter in the previous year.
Based on the above factors, Collegium Pharmaceutical, Inc gets an overall score of 5/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| ISIN | US19459J1043 |
| Market Cap | 864M |
|---|---|
| PE Ratio | 14.46 |
| Target Price | 42.8 |
| Beta | 0.76 |
| Dividend Yield | None |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for COLL using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
